[EN] PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS PYRIMIDONE CARBOXAMIDE UTILISÉS EN TANT QU'INHIBITEURS DE PDE2
申请人:MERCK SHARP & DOHME
公开号:WO2015096651A1
公开(公告)日:2015-07-02
Disclosed are pyrimidine carboxamide compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2), pharmaceutical compositions and uses thereof.
Diastereotopos-differentiation is the key feature of the catalytic C-H amination at the benzylic position of substrate 1. Essentially independent of the functional group X (X = COOMe, PO(OEt)(2), SO(2)Ph, NO(2), CN, OAc), the depicted products 2 are formed with good (dr = 80/20) to excellent (dr > 95/5) diastereoselectivity. The reaction proceeds without racemization and possesses potential for the C-H amination of open-chain substrates.
PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS